Eagle Pharma (EGRX) Sell Off Overdone - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Eagle Pharmaceuticals (EGRX) PT Lowered to $98 at Piper Jaffray Following CRL
March 18, 2016 12:07 PM EDTPiper Jaffray analyst David Amsellem lowered his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $98.00 (from $121.00) but maintained an Overweight rating after the company received a complete response letter (CRL) from the FDA related to its NDA for Kangio, its ready-to-use (RTU) form of bivalirudin. The... More
Mizuho Securities Cuts Price Target on Eagle Pharmaceuticals (EGRX) as Kangio is Delayed
March 18, 2016 11:13 AM EDTMizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $71.00 (from $81.00), on Kangio Delay. Eagle received a complete response letter (CRL) on Kangio, a reformulated version of MDCO's Angiomax. According to the letter, FDA wants further... More
Eagle Pharmaceuticals (EGRX) Announces Receipt of FDA Complete Response Letter for KANGIO NDA
March 18, 2016 6:52 AM EDTEagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use (RTU), stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial... More
